• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    4/17/25 4:30:51 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email
    false 0001347858 0001347858 2025-04-17 2025-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 17, 2025

     

     

     

    22nd Century Group, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Nevada   001-36338   98-0468420

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    321 Farmington Road, Mocksville, North Carolina

     

    27028

    (Address of Principal Executive Office)   (Zip Code)

     

    Registrant’s telephone number, including area code: (716) 270-1523

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of each exchange on which registered
    Common Stock, $0.00001 par value   XXII   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure.

     

    On April 17, 2025, 22nd Century Group, Inc. (the “Company” or “22nd Century”), announced a settlement agreement, subject to court approval, that would resolve certain shareholder derivative actions and release other potential derivative claims as outlined below. As the Company has previously disclosed, a shareholder of the Company filed a derivative action in the United States District Court for the Western District of New York alleging that the individual defendants breached their fiduciary or other duties by (1) causing the Company to engage in a paid stock promotion scheme (the “Stock Promotion Scheme”); and (2) issuing and/or causing the Company to issue false and misleading statements and omissions to the public that failed to disclose that (a) the Company engaged in the Stock Promotion Scheme, (b) the Company’s misconduct would subject it to heightened regulatory scrutiny, and (c) the Company failed to maintain internal controls resulting in an alleged investigation by the United States Securities and Exchange Commission (“SEC”). This action is In re 22nd Century Group, Inc. Derivative Litigation, Lead Case No. 1:19-cv-00479-JLS (the “Lead Action”). Also as previously disclosed, numerous other shareholder derivative cases were subsequently filed and consolidated into the Lead Action or into In re 22nd Century Group, Inc. Derivative Litigation, Lead Case No. A-20-808599-B pending in the Eighth Judicial District Court for the State of Nevada (collectively, together with the Lead Action, the “Derivative Actions”). These actions are Mathew v. Sicignano, et al., Supreme Court of the State of New York, County of Erie, Case No. 801786/2019, Rowley v. Sicignano, et al., Supreme Court of the State of New York, County of Erie, Case No. 807214/2019, Broccuto v. Cornell, et al., District Court of the State of Nevada, County of Clark, Case No. A-20-808599, Wayne v. Cornell, et al., District Court of the State of Nevada, County of Clark, Case No. A-20-808599 and Troup v. Sullivan, et al., United States District Court for the Western District of New York, Case No. 1:23-cv-00916.

     

    The parties to the Derivative Actions have reached an agreement that would resolve the Derivative Actions and release other potential derivative claims. If the United States District Court for the Western District of New York (“Court”) approves the proposed settlement: (i) insurance carriers for the Company would pay the attorneys for Plaintiffs $768,333; and (ii) the Company would maintain certain corporate governance practices for a period of at least five years. The settlement does not include any admission of liability, and the defendants expressly deny any wrongdoing. The terms and conditions of the proposed settlement are contained in the Stipulation and Agreement of Settlement (the “Settlement Agreement”).

     

    On April 7, 2025, the Court entered an Order in the Lead Action directing the Company to issue this Form 8-K to provide shareholders with the Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (the “Notice”) and the Settlement Agreement. The Notice and the Settlement Agreement are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. The Notice and Settlement Agreement are also available for review on the Investor Relations section of the Company’s website at

    https://ir.xxiicentury.com/.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, which are furnished herewith pursuant to and relate to this Item 7.01, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 hereto shall not be incorporated by reference into any filing or other document filed by the Company with the SEC pursuant to the Securities Act of 1933, as amended, the rules and regulations of the SEC thereunder, the Exchange Act, or the rules and regulations of the SEC thereunder except as shall be expressly set forth by specific reference in such filing or document.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following documents are furnished as exhibits to this Current Report on Form 8-K:

     

    99.1 Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
       
    99.2 Stipulation and Agreement of Settlement
       
    104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      22nd Century Group, Inc.
       
      /s/ Lawrence Firestone
    Date: April 17, 2025 Lawrence Firestone
      Chief Executive Officer

     

     

     

    Get the next $XXII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      9/12/24 5:00:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      5/31/24 4:05:20 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      1/8/24 8:04:11 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    SEC Filings

    See more
    • SEC Form EFFECT filed by 22nd Century Group Inc.

      EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

      5/23/25 12:15:08 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PRE 14A filed by 22nd Century Group Inc.

      PRE 14A - 22nd Century Group, Inc. (0001347858) (Filer)

      5/22/25 4:45:37 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - 22nd Century Group, Inc. (0001347858) (Filer)

      5/22/25 4:30:26 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      12/3/24 11:18:54 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      11/14/24 5:56:57 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by 22nd Century Group Inc.

      SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

      10/23/24 7:27:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:37:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salhany Lucille S was granted 2,472 shares, increasing direct ownership by 49,440% to 2,477 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:35:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Arno Andrew was granted 4,237 shares, increasing direct ownership by 9,015% to 4,284 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:30:19 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Financials

    Live finance-specific insights

    See more
    • 22nd Century Group Reports First Quarter 2025 Financial Results

      Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

      5/13/25 6:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

      For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

      12/23/21 9:06:12 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • 22nd Century to Present at the Emerging Growth Conference on May 21, 2025

      MOCKSVILLE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, (the "Company") is pleased to announce that Larry Firestone, Chief Executive Officer, will present a brief corporate update at the Emerging Growth Conference on Wednesday, May 21, 2025, at 12:00 pm Eastern Time. Mr. Firestone will provide updates to recent company advancements and may subsequently open the floor for questions. Questions may be submitted in advance to [email protected]. Investors can register in advance to attend the conference

      5/19/25 4:15:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

      Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      7/21/22 9:12:19 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on 22nd Century Group with a new price target

      Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      6/15/22 7:42:24 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Roth Capital initiated coverage on 22nd Century Group with a new price target

      Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

      3/8/22 9:21:23 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    See more
    • 22nd Century Announces Resignation of John Miller as President of Tobacco

      Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

      5/30/24 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

      BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

      9/12/22 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

      CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea

      6/16/22 8:30:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care